Vapotherm Inc. (NYSE: VAPO), a global medical technology company committed to the development and commercialization of its proprietary Vapotherm high velocity therapy® products, has recently announced the successful completion of a private placement financing (“PIPE”) with a select group of institutional and accredited investors. Through the Purchase Agreement, the Company raised approximately $23.0 million in gross proceeds before deducting fees and other offering expenses. Furthermore, 17,502,244 shares of its common stock and pre-funded warrants to purchase up to 4,402,508 shares of its common stock were issued, along with accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant purchased by investors. The closing is expected to occur on February 10, 2023, subject to customary closing conditions.
The Company is eager to put the proceeds from this offering to good use, looking to bolster their sales and marketing efforts, as well as their overall working capital. These new funds will be put towards general corporate purposes and help the Company continue to grow and succeed.
William Blair & Company, L.L.C. had the exclusive opportunity to act as the placement agent for this offering. They were the only ones entrusted with this responsibility, making it a prestigious opportunity for the firm.
Vapotherm has committed to registering the securities sold in the PIPE with the Securities and Exchange Commission. This registration is necessary in order to offer the securities for sale in the United States, as they have not been registered under the Securities Act of 1933, or any other state or jurisdictional laws. The Purchase Agreement outlines the terms of the registration process, providing a necessary exemption from the registration requirements.
These securities are now available for sale, and interested investors can take advantage of this opportunity in any state or jurisdiction in which they are legally eligible. All applicable securities laws must be complied with in order to complete the sale. Don’t miss out on this chance to invest in a secure and rewarding future!
Vapotherm, Inc., a publicly traded leader in advanced respiratory technology, is revolutionizing the way we treat breathing disorders. Located in Exeter, New Hampshire, USA, their innovative, comfortable and non-invasive high velocity therapy® systems have already been used to treat over 3.6 million patients – providing them with much-needed relief from chronic or acute respiratory issues. Now, with the help of Vapotherm, patients can breathe easier knowing there is a better way.
Vapotherm high velocity therapy is revolutionizing the treatment of respiratory distress. Patients no longer have to rely on uncomfortable, invasive masks to receive the care they need—HVT 2.0 and Precision Flow systems provide a mask-free, non-invasive option for fast, safe relief of symptoms such as hypercapnia, hypoxemia, and dyspnea. With optimally conditioned breathing gases, patients can remain comfortable while talking, eating, drinking, and taking oral medication during treatment. Vapotherm high velocity therapy is the front-line tool for relieving respiratory distress and improving patient care.